Friedreich Ataxia

Mendelian MONDO:0100339 Pathograph 21 Hereditary Ataxia Mitochondrial Disorder

Friedreich ataxia (FRDA) is the most common inherited ataxia, caused by homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene encoding frataxin, a mitochondrial protein essential for iron-sulfur cluster biogenesis. Frataxin deficiency leads to mitochondrial iron accumulation, impaired oxidative phosphorylation, and oxidative stress. The disease is characterized by progressive gait and limb ataxia, dysarthria, loss of deep tendon reflexes, sensory neuropathy, hypertrophic cardiomyopathy, scoliosis, pes cavus, and diabetes mellitus. Onset is typically around puberty with progressive disability and shortened lifespan, often due to cardiac complications.

Ask OpenScientist

Ask a research question about Friedreich Ataxia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
0
Definitions
1
Inheritance
8
Pathophysiology
0
Histopathology
10
Phenotypes
1
Hypotheses
21
Pathograph
1
Genes
5
Treatments
0
Subtypes
0
Differentials
0
Datasets
1
Trials
0
Models
1
Deep Research
🔗

Mappings

MONDO
MONDO:0100339 Friedreich ataxia
skos:exactMatch Orphanet ORPHA:95
Orphanet lists MONDO:0100339 as an exact cross-reference for the ORPHA:95 Friedreich ataxia record.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Friedreich ataxia is caused by biallelic pathogenic FXN alleles, most often homozygous intron 1 GAA repeat expansions, and follows autosomal recessive inheritance.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
Defines the inheritance pattern and the usual biallelic FXN repeat-expansion genotype.
ORPHA:95 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for Friedreich ataxia.
◈

Mechanistic Hypotheses

1
Canonical FXN Loss-of-Function Mitochondrial Pathograph
canonical_fxn_loss_of_function CANONICAL
Biallelic FXN intron 1 GAA repeat expansion causes epigenetic transcriptional silencing and frataxin deficiency. Frataxin deficiency impairs mitochondrial Fe-S cluster biogenesis, oxidative phosphorylation, and iron handling, creating tissue-selective vulnerability in dorsal root ganglion sensory neurons, dentate/spinal pathways, cardiomyocytes, pancreatic beta cells, and the skeleton.
Pathograph links
FXN GAA Repeat Expansion and Epigenetic Silencing -> Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect INDIRECT KNOWN INTERMEDIATES FXN transcriptional silencing reduces frataxin, the mitochondrial protein required for the canonical FRDA loss-of-function path. Intermediates: expanded intron 1 GAA repeat; repressive chromatin flanking the repeat; reduced FXN transcription
Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect -> Mitochondrial Bioenergetic Failure and Oxidative Stress DIRECT Defective Fe-S cluster biogenesis lowers activity of mitochondrial respiratory-chain and Fe-S enzymes, producing energy failure, iron dysregulation, and oxidative stress.
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Dorsal Root Ganglion Sensory Neuronopathy INDIRECT KNOWN INTERMEDIATES Sensory neurons in dorsal root ganglia are especially vulnerable to the mitochondrial consequences of frataxin deficiency, causing the proprioceptive sensory branch of FRDA. Intermediates: reduced respiratory-chain complex I and II activity; mitochondrial superoxide generation; sensory neuron lethality
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Dentate Nucleus and Spinocerebellar Tract Degeneration INDIRECT KNOWN INTERMEDIATES Mitochondrial frataxin deficiency also injures cerebellar dentate and spinal tract systems, adding central cerebellar and corticospinal components to the sensory ataxia path. Intermediates: dentate nucleus atrophy; dorsal column and spinocerebellar tract fiber loss; corticospinal tract degeneration
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Muscle Weakness INDIRECT KNOWN INTERMEDIATES Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and contributes to progressive limb weakness and fatigue. Intermediates: skeletal muscle mitochondrial dysfunction; neuromuscular weakness
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Cardiomyocyte Mitochondrial Injury INDIRECT KNOWN INTERMEDIATES Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial injury and structural myocyte pathology, producing the cardiac branch of FRDA. Intermediates: mitochondrial iron dysmetabolism; cardiomyocyte hypertrophy; disrupted intercalated discs
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Pancreatic Beta-Cell Apoptosis INDIRECT KNOWN INTERMEDIATES In pancreatic beta cells, frataxin deficiency causes mitochondrial dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining the diabetes branch of FRDA. Intermediates: beta-cell mitochondrial dysfunction; oxidative stress-mediated intrinsic apoptosis
Mitochondrial Bioenergetic Failure and Oxidative Stress -> Progressive Skeletal Deformity INDIRECT KNOWN INTERMEDIATES Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal involvement converge on progressive spinal and foot deformity. Intermediates: proprioceptive impairment; progressive neuromuscular weakness; skeletal involvement
Dorsal Root Ganglion Sensory Neuronopathy -> Peripheral Neuropathy DIRECT DRG and sensory nerve injury produces the peripheral sensory neuropathy phenotype with loss of proprioception and vibration sense.
Dorsal Root Ganglion Sensory Neuronopathy -> Progressive Gait and Limb Ataxia INDIRECT KNOWN INTERMEDIATES Loss of proprioceptive sensory input from DRG injury produces sensory ataxia that combines with cerebellar pathway degeneration. Intermediates: impaired proprioception; impaired vibration sense; sensory ataxia
Dentate Nucleus and Spinocerebellar Tract Degeneration -> Progressive Gait and Limb Ataxia DIRECT Dentate and spinocerebellar tract degeneration add a cerebellar motor control deficit to the sensory ataxia branch.
Dentate Nucleus and Spinocerebellar Tract Degeneration -> Dysarthria INDIRECT KNOWN INTERMEDIATES Cerebellar and corticospinal pathway degeneration contributes to impaired speech motor coordination. Intermediates: cerebellar motor pathway dysfunction; corticospinal tract degeneration
Dentate Nucleus and Spinocerebellar Tract Degeneration -> Dysphagia INDIRECT KNOWN INTERMEDIATES Cerebellar and corticospinal pathway dysfunction can impair swallowing motor coordination, producing dysphagia as part of the classical FRDA neurologic phenotype. Intermediates: impaired bulbar motor coordination; progressive neurologic dysfunction
Dentate Nucleus and Spinocerebellar Tract Degeneration -> Nystagmus INDIRECT KNOWN INTERMEDIATES Central nervous system involvement in FRDA produces oculomotor disturbance, including nystagmus. Intermediates: cerebellar oculomotor pathway dysfunction; abnormal saccades and square wave jerks
Cardiomyocyte Mitochondrial Injury -> Hypertrophic Cardiomyopathy DIRECT Cardiomyocyte hypertrophy and mitochondrial injury produce the common hypertrophic cardiomyopathy phenotype.
Pancreatic Beta-Cell Apoptosis -> Diabetes Mellitus DIRECT Beta-cell dysfunction and death reduce insulin secretory capacity and produce the FRDA diabetes phenotype.
Progressive Skeletal Deformity -> Scoliosis DIRECT Progressive skeletal deformity manifests as scoliosis in the FRDA phenotype list.
Progressive Skeletal Deformity -> Pes Cavus DIRECT Progressive skeletal and neuromuscular involvement manifests as pes cavus in the FRDA phenotype list.
Show evidence (1 reference)
PMID:21315377 SUPPORT Human Clinical
"Deficiency of frataxin, a small mitochondrial protein, is responsible for all clinical and morphological manifestations of FRDA."
Establishes frataxin deficiency as the common causal mechanism underlying the multisystem FRDA phenotype.
⚙

Pathophysiology

8
FXN GAA Repeat Expansion and Epigenetic Silencing
Biallelic expansion of the GAA repeat in intron 1 of FXN produces a non-coding repeat-expansion loss-of-expression mechanism. Repressive chromatin around the expanded repeat lowers FXN transcription and reduces frataxin abundance, establishing the upstream genetic lesion for all downstream FRDA pathograph paths.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
regulation of gene expression link ↓ DECREASED chromatin organization link ↕ DYSREGULATED
Downstream
Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect FXN transcriptional silencing reduces frataxin, the mitochondrial protein required for the canonical FRDA loss-of-function path. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (2 references)
PMID:32826895 SUPPORT In Vitro
"Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."
Defines the upstream FXN repeat-expansion silencing mechanism in a human iPSC-derived DRG organoid study.
PMID:21315377 SUPPORT Human Clinical
"The pathogenic mutation in Friedreich's ataxia (FRDA) is a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat expansion on chromosome 9q13 that causes a transcriptional defect of the frataxin gene."
Human pathology review states that the repeat expansion causes a transcriptional defect of FXN.
Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect
Reduced frataxin impairs mitochondrial iron-sulfur cluster biosynthesis, oxidative phosphorylation, and iron handling. This common biochemical lesion feeds the tissue-specific branches that explain sensory ataxia, dysarthria, cardiomyopathy, diabetes, and skeletal deformity.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
sensory neuron of dorsal root ganglion link neuron link cardiac muscle cell link pancreatic beta cell link
iron-sulfur cluster assembly link ↓ DECREASED oxidative phosphorylation link ↓ DECREASED intracellular iron ion homeostasis link ↕ DYSREGULATED
mitochondrion link
dorsal root ganglion link cerebellum link heart link pancreas link
Downstream
Mitochondrial Bioenergetic Failure and Oxidative Stress Defective Fe-S cluster biogenesis lowers activity of mitochondrial respiratory-chain and Fe-S enzymes, producing energy failure, iron dysregulation, and oxidative stress. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (3 references)
PMID:14653404 SUPPORT Human Clinical
"the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin, leading to potentially harmful oxidative injury associated with excessive iron deposits in mitochondria. In addition, pathogenesis may involve a primary defect in synthesis of iron-sulfur..."
Confirms frataxin deficiency, mitochondrial iron accumulation, and iron-sulfur cluster assembly defect as the pathogenic mechanism.
PMID:31456208 SUPPORT Human Clinical
"This protein is essential for mitochondrial function by the involvement of iron-sulfur cluster biogenesis. The effects of its deficiency also include disruption of cellular, particularly mitochondrial, iron homeostasis, i.e., relatively more iron accumulated in mitochondria and less iron..."
Confirms frataxin's role in iron-sulfur cluster biogenesis and mitochondrial iron accumulation upon deficiency.
PMID:39337401 SUPPORT Human Clinical
"At a cellular level, frataxin deficiency results in insufficient iron-sulfur cluster biosynthesis and impaired mitochondrial function and adenosine triphosphate production."
Recent review states the core biochemical consequence that bridges frataxin deficiency to mitochondrial energy failure.
Mitochondrial Bioenergetic Failure and Oxidative Stress
Frataxin-deficient cells show impaired electron transport, altered mitochondrial morphology, abnormal iron handling, and oxidative stress. This shared mitochondrial stress state is the branch point for sensory neuronal, cerebellar, cardiac, pancreatic beta-cell, and musculoskeletal outcomes.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
sensory neuron of dorsal root ganglion link cardiac muscle cell link pancreatic beta cell link
oxidative phosphorylation link ↓ DECREASED response to oxidative stress link ↑ INCREASED intracellular iron ion homeostasis link ↕ DYSREGULATED
mitochondrion link
Downstream
Dorsal Root Ganglion Sensory Neuronopathy Sensory neurons in dorsal root ganglia are especially vulnerable to the mitochondrial consequences of frataxin deficiency, causing the proprioceptive sensory branch of FRDA. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Dentate Nucleus and Spinocerebellar Tract Degeneration Mitochondrial frataxin deficiency also injures cerebellar dentate and spinal tract systems, adding central cerebellar and corticospinal components to the sensory ataxia path. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Muscle Weakness Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and contributes to progressive limb weakness and fatigue. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Cardiomyocyte Mitochondrial Injury Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial injury and structural myocyte pathology, producing the cardiac branch of FRDA. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Pancreatic Beta-Cell Apoptosis In pancreatic beta cells, frataxin deficiency causes mitochondrial dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining the diabetes branch of FRDA. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Progressive Skeletal Deformity Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal involvement converge on progressive spinal and foot deformity. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:38129330 SUPPORT Model Organism
"Mitochondrial dysfunction, a reduction in the activity of iron-sulfur enzymes, iron accumulation, and increased oxidative stress have been described."
Summarizes the shared mitochondrial and oxidative-stress state produced by frataxin deficiency.
Dorsal Root Ganglion Sensory Neuronopathy
FRDA injures dorsal root ganglion sensory neurons and their satellite-cell niche, causing loss of proprioceptive and vibration-sense input. This explains sensory neuropathy, areflexia, impaired balance, and a major upstream component of progressive gait and limb ataxia.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
sensory neuron of dorsal root ganglion link glial cell link
dorsal root ganglion link
Downstream
Peripheral Neuropathy DRG and sensory nerve injury produces the peripheral sensory neuropathy phenotype with loss of proprioception and vibration sense. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Progressive Gait and Limb Ataxia Loss of proprioceptive sensory input from DRG injury produces sensory ataxia that combines with cerebellar pathway degeneration. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:27142428 SUPPORT Human Clinical
"FA causes major primary changes in satellite cells and inflammatory destruction of neurons."
Human DRG pathology supports neuron and satellite-cell injury as a proximal neuropathologic event.
Dentate Nucleus and Spinocerebellar Tract Degeneration
FRDA affects the dentate nucleus, dorsal columns, spinocerebellar tracts, and corticospinal tracts. Central cerebellar and spinal pathway involvement combines with sensory neuronopathy to drive progressive ataxia and dysarthria.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
neuron link
dentate nucleus link spinal cord link
Downstream
Progressive Gait and Limb Ataxia Dentate and spinocerebellar tract degeneration add a cerebellar motor control deficit to the sensory ataxia branch. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Dysarthria Cerebellar and corticospinal pathway degeneration contributes to impaired speech motor coordination. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Dysphagia Cerebellar and corticospinal pathway dysfunction can impair swallowing motor coordination, producing dysphagia as part of the classical FRDA neurologic phenotype. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Nystagmus Central nervous system involvement in FRDA produces oculomotor disturbance, including nystagmus. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:21315377 SUPPORT Human Clinical
"Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
Supports dentate nucleus and corticospinal tract degeneration as intrinsic CNS lesions in FRDA.
Cardiomyocyte Mitochondrial Injury
In the heart, frataxin deficiency produces cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs. The clinical downstream manifestation is hypertrophic cardiomyopathy, a major determinant of premature mortality in FRDA.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
cardiac muscle cell link
oxidative phosphorylation link ↓ DECREASED
myocardium link
Downstream
Hypertrophic Cardiomyopathy Cardiomyocyte hypertrophy and mitochondrial injury produce the common hypertrophic cardiomyopathy phenotype. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:28789479 SUPPORT Human Clinical
"Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."
Human tissue pathology supports the cardiomyocyte injury node.
Pancreatic Beta-Cell Apoptosis
Frataxin-deficient pancreatic beta cells undergo mitochondrial dysfunction, oxidative stress, and intrinsic apoptosis, explaining why a subset of FRDA patients develop diabetes mellitus.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
pancreatic beta cell link
apoptotic process link ↑ INCREASED response to oxidative stress link ↑ INCREASED
pancreas link
Downstream
Diabetes Mellitus Beta-cell dysfunction and death reduce insulin secretory capacity and produce the FRDA diabetes phenotype. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:25552656 SUPPORT In Vitro
"Here we show that β-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis."
Demonstrates the beta-cell apoptosis mechanism downstream of frataxin deficiency.
Progressive Skeletal Deformity
FRDA skeletal involvement includes progressive scoliosis and pes cavus. The mechanism is represented as an indirect downstream path from the FXN loss-of-function multisystem disorder through neuromuscular imbalance, weakness, sensory neuropathy, and skeletal involvement.
Canonical FXN Loss-of-Function Mitochondrial Pathograph
skeleton link
Downstream
Scoliosis Progressive skeletal deformity manifests as scoliosis in the FRDA phenotype list. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Pes Cavus Progressive skeletal and neuromuscular involvement manifests as pes cavus in the FRDA phenotype list. Canonical FXN Loss-of-Function Mitochondrial Pathograph
Show evidence (1 reference)
PMID:21315377 SUPPORT Human Clinical
"Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."
Human clinical-pathology review supports scoliosis and pes cavus as FRDA skeletal manifestations.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Friedreich Ataxia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 1
Hypertrophic Cardiomyopathy FREQUENT Hypertrophic cardiomyopathy (HP:0001639)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
Cardiomyopathy is listed as part of the classical Friedreich ataxia phenotype.
ORPHA:95 SUPPORT Other
"HP:0001638 | Cardiomyopathy | Frequent (79-30%)"
Orphanet's HPO table supports cardiomyopathy as a frequent Friedreich ataxia phenotype.
Digestive 1
Dysphagia OCCASIONAL Dysphagia (HP:0002015)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
Lists dysphagia among the classical FRDA clinical features.
ORPHA:95 SUPPORT Other
"HP:0002015 | Dysphagia | Occasional (29-5%)"
Orphanet's HPO table supports dysphagia as an occasional Friedreich ataxia phenotype.
Endocrine 1
Diabetes Mellitus OCCASIONAL Diabetes mellitus (HP:0000819)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"scoliosis, foot deformities, cardiomyopathy and diabetes."
Diabetes is part of the classical phenotype description.
ORPHA:95 SUPPORT Other
"HP:0000819 | Diabetes mellitus | Occasional (29-5%)"
Orphanet's HPO table supports diabetes mellitus as an occasional Friedreich ataxia phenotype.
Eye 1
Nystagmus FREQUENT Nystagmus (HP:0000639)
Show evidence (3 references)
PMID:23859346 SUPPORT Human Clinical
"dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes"
Lists eye movement abnormalities among the classical FRDA clinical features.
PMID:21315377 SUPPORT Human Clinical
"Many patients with FRDA have nystagmus."
Directly supports nystagmus as a common FRDA neurologic manifestation.
ORPHA:95 SUPPORT Other
"HP:0000639 | Nystagmus | Frequent (79-30%)"
Orphanet's HPO table supports nystagmus as a frequent Friedreich ataxia phenotype.
Limbs 1
Pes Cavus FREQUENT Pes cavus (HP:0001761)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"Early-onset cases tend to have more rapid progression and a higher frequency of non-neurological features such as diabetes, cardiomyopathy, scoliosis and pes cavus."
Pes cavus is more frequent in early-onset cases.
ORPHA:95 SUPPORT Other
"HP:0001761 | Pes cavus | Frequent (79-30%)"
Orphanet's HPO table supports pes cavus as a frequent Friedreich ataxia phenotype.
Musculoskeletal 2
Muscle Weakness FREQUENT Muscle weakness (HP:0001324)
Show evidence (3 references)
PMID:23859346 SUPPORT Human Clinical
"leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
Lists leg weakness among the classical FRDA clinical features.
PMID:21315377 SUPPORT Human Clinical
"The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities"
Identifies distal extremity weakness among the most frequent neurologic signs in FRDA.
ORPHA:95 SUPPORT Other
"HP:0001324 | Muscle weakness | Frequent (79-30%)"
Orphanet's HPO table supports muscle weakness as a frequent Friedreich ataxia phenotype.
Scoliosis FREQUENT Scoliosis (HP:0002650)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"scoliosis, foot deformities, cardiomyopathy and diabetes."
Scoliosis is part of the classical phenotype.
ORPHA:95 SUPPORT Other
"HP:0002650 | Scoliosis | Frequent (79-30%)"
Orphanet's HPO table supports scoliosis as a frequent Friedreich ataxia phenotype.
Nervous System 3
Progressive Gait and Limb Ataxia VERY_FREQUENT Ataxia (HP:0001251)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
Comprehensive description of the classical Friedreich ataxia phenotype with ataxia as the core feature.
ORPHA:95 SUPPORT Other
"HP:0002070 | Limb ataxia | Very frequent (99-80%)"
Orphanet's HPO table supports very frequent limb ataxia in Friedreich ataxia.
Dysarthria VERY_FREQUENT Dysarthria (HP:0001260)
Show evidence (2 references)
PMID:23859346 SUPPORT Human Clinical
"gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia"
Dysarthria is part of the classical phenotype.
ORPHA:95 SUPPORT Other
"HP:0001260 | Dysarthria | Very frequent (99-80%)"
Orphanet's HPO table supports dysarthria as a very frequent Friedreich ataxia phenotype.
Peripheral Neuropathy VERY_FREQUENT Peripheral neuropathy (HP:0009830)
🧬

Genetic Associations

1
FXN (GAA Trinucleotide Repeat Expansion)
Autosomal recessive inheritance
Show evidence (3 references)
PMID:14653404 SUPPORT Human Clinical
"the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin"
Confirms GAA expansion as the causative mutation leading to frataxin deficiency.
PMID:23859346 SUPPORT Human Clinical
"Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
Confirms autosomal recessive inheritance with homozygous GAA expansion in FXN.
CGGV:assertion_ec3f674b-1e71-4254-a0f9-f8909becff59-2017-12-22T170000.000Z SUPPORT Other
"FXN | HGNC:3951 | Friedreich ataxia | MONDO:0100339 | AR | Definitive"
ClinGen classifies the FXN-Friedreich ataxia gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Treatments

5
Omaveloxolone
Action: pharmacotherapy MAXO:0000058
Agent: omaveloxolone ↗
Approved pharmacotherapy for individuals with Friedreich ataxia aged 16 years and older. It is used to slow neurologic progression by modulating oxidative-stress and mitochondrial-function pathways rather than restoring FXN expression directly.
Mechanism Target:
MODULATES Mitochondrial Bioenergetic Failure and Oxidative Stress — Omaveloxolone acts downstream of FXN silencing by targeting the oxidative stress and mitochondrial dysfunction branch of the pathograph.
Show evidence (1 reference)
PMID:39115603 SUPPORT Human Clinical
"Currently therapies focus on reducing oxidative stress and improving mitochondrial function, modulating frataxin controlled metabolic pathways and gene replacement and editing."
Supports placing approved and emerging pharmacotherapies on the oxidative-stress/mitochondrial-function mechanism branch.
Show evidence (1 reference)
PMID:39115603 SUPPORT Human Clinical
"Approval of omaveloxolone, the first treatment for individuals with FRDA aged 16 years and over, has created much excitement for both those living with FRDA and those that care for them."
Recent review states that omaveloxolone is the first approved FRDA treatment for patients aged 16 years and older.
Supportive and Symptomatic Care
Action: supportive care MAXO:0000950
Multidisciplinary care including physical therapy, occupational therapy, speech therapy, and orthopedic management of scoliosis and foot deformities.
Show evidence (1 reference)
PMID:29053830 SUPPORT Human Clinical
"Management of Freidreich's ataxia is currently focussed on symptomatic management, delivered by the multidisciplinary team."
Confirms that current management is multidisciplinary and symptomatic.
Cardiac Management
Action: pharmacotherapy MAXO:0000058
Regular cardiac monitoring and treatment of cardiomyopathy and arrhythmias. ACE inhibitors and beta-blockers may be used for heart failure management.
Investigational Frataxin-Restoring Therapies
Action: gene therapy MAXO:0001001
Clinical trials are investigating agents that address the aberrant silencing of the frataxin gene, including histone deacetylase inhibitors, gene therapy approaches, and frataxin replacement strategies.
Show evidence (1 reference)
PMID:29053830 SUPPORT Human Clinical
"Phase II clinical trials in agents that address the abberrant silencing of the frataxin gene need to be translated into large placebo-controlled Phase III trials to help establish their therapeutic potential."
Confirms ongoing clinical development of frataxin-restoring therapies.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for autosomal recessive inheritance pattern and carrier testing for family members.
🔬

Clinical Trials

1
NCT02255435 PHASE_II COMPLETED
Completed phase 2 MOXIe trial of RTA 408, also known as omaveloxolone, evaluating safety, pharmacodynamics, cycling work, and 48-week modified Friedreich's Ataxia Rating Scale change in Friedreich ataxia.
Target Phenotypes: Ataxia ↗ Dysarthria ↗
Show evidence (1 reference)
clinicaltrials:NCT02255435 SUPPORT Human Clinical
"Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work."
ClinicalTrials.gov record documents the completed omaveloxolone MOXIe trial and its neurologic functional endpoints in FRDA.
{ }

Source YAML

click to show 
name: Friedreich Ataxia
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-04-28T03:53:25Z"
description: >
  Friedreich ataxia (FRDA) is the most common inherited ataxia, caused by
  homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene
  encoding frataxin, a mitochondrial protein essential for iron-sulfur cluster
  biogenesis. Frataxin deficiency leads to mitochondrial iron accumulation,
  impaired oxidative phosphorylation, and oxidative stress. The disease is
  characterized by progressive gait and limb ataxia, dysarthria, loss of
  deep tendon reflexes, sensory neuropathy, hypertrophic cardiomyopathy,
  scoliosis, pes cavus, and diabetes mellitus. Onset is typically around
  puberty with progressive disability and shortened lifespan, often due
  to cardiac complications.
category: Mendelian
disease_term:
  preferred_term: Friedreich Ataxia
  term:
    id: MONDO:0100339
    label: Friedreich ataxia
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0100339
      label: Friedreich ataxia
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:95
    mapping_justification: >-
      Orphanet lists MONDO:0100339 as an exact cross-reference for the
      ORPHA:95 Friedreich ataxia record.
external_assertions:
- name: Orphanet Friedreich ataxia structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:95
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=95
  description: >-
    Orphanet records Friedreich ataxia as ORPHA:95 and provides external
    cross-references supporting this entry's disease identity.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0100339 | Exact"
    explanation: Orphanet lists the MONDO disease identifier as an exact cross-reference.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:229300 | Exact"
    explanation: Orphanet lists the primary OMIM disease identifier as an exact cross-reference.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:8A03.10 | Exact"
    explanation: Orphanet lists the ICD-11 disease code as an exact cross-reference.
inheritance:
- name: Autosomal recessive inheritance
  description: >
    Friedreich ataxia is caused by biallelic pathogenic FXN alleles, most often
    homozygous intron 1 GAA repeat expansions, and follows autosomal recessive
    inheritance.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
    explanation: Defines the inheritance pattern and the usual biallelic FXN repeat-expansion genotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for Friedreich ataxia.
parents:
- Hereditary Ataxia
- Mitochondrial Disorder
prevalence:
- population: Global
  percentage: "0.003"
  notes: Estimated prevalence of 1 in 29,000-50,000 in European populations. More rare in East Asian and sub-Saharan African populations.
- population: Europe (Orphanet)
  percentage: 1-9 / 100 000
  notes: Orphanet classifies European point prevalence as 1-9 per 100,000.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Point prevalence | PMID:20301458,PMID:23859338"
    explanation: Orphanet's epidemiology table provides the European point-prevalence class for Friedreich ataxia.
progression:
- phase: Onset
  age_range: Childhood to adolescence
  notes: Typical onset around puberty (ages 10-15). Late-onset forms (after age 25) are associated with smaller GAA expansions and slower progression.
  evidence:
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet lists childhood as an age-of-onset category for Friedreich ataxia.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: Orphanet lists adolescence as an age-of-onset category for Friedreich ataxia.
pathophysiology:
- name: FXN GAA Repeat Expansion and Epigenetic Silencing
  description: >
    Biallelic expansion of the GAA repeat in intron 1 of FXN produces a
    non-coding repeat-expansion loss-of-expression mechanism. Repressive
    chromatin around the expanded repeat lowers FXN transcription and reduces
    frataxin abundance, establishing the upstream genetic lesion for all
    downstream FRDA pathograph paths.
  gene:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DECREASED
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:32826895
    reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."
    explanation: Defines the upstream FXN repeat-expansion silencing mechanism in a human iPSC-derived DRG organoid study.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pathogenic mutation in Friedreich's ataxia (FRDA) is a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat expansion on chromosome 9q13 that causes a transcriptional defect of the frataxin gene."
    explanation: Human pathology review states that the repeat expansion causes a transcriptional defect of FXN.
  downstream:
  - target: Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect
    description: >
      FXN transcriptional silencing reduces frataxin, the mitochondrial protein
      required for the canonical FRDA loss-of-function path.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - expanded intron 1 GAA repeat
    - repressive chromatin flanking the repeat
    - reduced FXN transcription
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:32826895
      reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These results strongly suggest that removal of the repressed chromatin flanking the GAA tract might contribute to rescue FXN total expression and fully revert the pathological hallmarks of FRDA DRG neurons."
      explanation: Links repressed chromatin around the repeat to reduced FXN expression and DRG neuronal pathology.
- name: Frataxin Deficiency and Iron-Sulfur Cluster Assembly Defect
  description: >
    Reduced frataxin impairs mitochondrial iron-sulfur cluster biosynthesis,
    oxidative phosphorylation, and iron handling. This common biochemical lesion
    feeds the tissue-specific branches that explain sensory ataxia, dysarthria,
    cardiomyopathy, diabetes, and skeletal deformity.
  gene:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: iron-sulfur cluster assembly
    term:
      id: GO:0016226
      label: iron-sulfur cluster assembly
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: intracellular iron ion homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
    modifier: DYSREGULATED
  locations:
  - preferred_term: dorsal root ganglion
    term:
      id: UBERON:0000044
      label: dorsal root ganglion
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:14653404
    reference_title: "Friedreich ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin, leading to potentially harmful oxidative injury associated with excessive iron deposits in mitochondria. In addition, pathogenesis may involve a primary defect in synthesis of iron-sulfur cluster containing enzymes."
    explanation: Confirms frataxin deficiency, mitochondrial iron accumulation, and iron-sulfur cluster assembly defect as the pathogenic mechanism.
  - reference: PMID:31456208
    reference_title: "Iron Pathophysiology in Friedreich's Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This protein is essential for mitochondrial function by the involvement of iron-sulfur cluster biogenesis. The effects of its deficiency also include disruption of cellular, particularly mitochondrial, iron homeostasis, i.e., relatively more iron accumulated in mitochondria and less iron presented in cytosol."
    explanation: Confirms frataxin's role in iron-sulfur cluster biogenesis and mitochondrial iron accumulation upon deficiency.
  - reference: PMID:39337401
    reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At a cellular level, frataxin deficiency results in insufficient iron-sulfur cluster biosynthesis and impaired mitochondrial function and adenosine triphosphate production."
    explanation: Recent review states the core biochemical consequence that bridges frataxin deficiency to mitochondrial energy failure.
  downstream:
  - target: Mitochondrial Bioenergetic Failure and Oxidative Stress
    description: >
      Defective Fe-S cluster biogenesis lowers activity of mitochondrial
      respiratory-chain and Fe-S enzymes, producing energy failure, iron
      dysregulation, and oxidative stress.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:38129330
      reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "frataxin deficiency resulted in lower activity and levels of the electron transport complexes, mainly complexes I and II."
      explanation: Directly links frataxin deficiency to respiratory-chain complex impairment in DRG models.
- name: Mitochondrial Bioenergetic Failure and Oxidative Stress
  description: >
    Frataxin-deficient cells show impaired electron transport, altered
    mitochondrial morphology, abnormal iron handling, and oxidative stress. This
    shared mitochondrial stress state is the branch point for sensory neuronal,
    cerebellar, cardiac, pancreatic beta-cell, and musculoskeletal outcomes.
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: intracellular iron ion homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
    modifier: DYSREGULATED
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  evidence:
  - reference: PMID:38129330
    reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mitochondrial dysfunction, a reduction in the activity of iron-sulfur enzymes, iron accumulation, and increased oxidative stress have been described."
    explanation: Summarizes the shared mitochondrial and oxidative-stress state produced by frataxin deficiency.
  downstream:
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    description: >
      Sensory neurons in dorsal root ganglia are especially vulnerable to the
      mitochondrial consequences of frataxin deficiency, causing the
      proprioceptive sensory branch of FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced respiratory-chain complex I and II activity
    - mitochondrial superoxide generation
    - sensory neuron lethality
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:38129330
      reference_title: "Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in Friedreich Ataxia models."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Dorsal root ganglion (DRG) sensory neurons are among the cellular types most affected in the early stages of this disease."
      explanation: Establishes selective DRG sensory neuron vulnerability.
  - target: Dentate Nucleus and Spinocerebellar Tract Degeneration
    description: >
      Mitochondrial frataxin deficiency also injures cerebellar dentate and
      spinal tract systems, adding central cerebellar and corticospinal
      components to the sensory ataxia path.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - dentate nucleus atrophy
    - dorsal column and spinocerebellar tract fiber loss
    - corticospinal tract degeneration
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The neurological phenotype reflects lesions in dorsal root ganglia (DRG), sensory peripheral nerves, corticospinal tracts, and dentate nuclei (DN)."
      explanation: Human pathology review maps FRDA neurologic manifestations to DRG, sensory nerve, corticospinal tract, and dentate nucleus lesions.
  - target: Muscle Weakness
    description: >
      Mitochondrial bioenergetic failure in FRDA affects skeletal muscle and
      contributes to progressive limb weakness and fatigue.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - skeletal muscle mitochondrial dysfunction
    - neuromuscular weakness
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:39337401
      reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "FRDA displays skeletal muscle involvement, which contributes to the weakness and marked fatigue evident throughout the course of the disease."
      explanation: Links the shared mitochondrial branch to skeletal muscle involvement and weakness in FRDA.
  - target: Cardiomyocyte Mitochondrial Injury
    description: >
      Frataxin-deficient cardiomyocytes accumulate iron-positive mitochondrial
      injury and structural myocyte pathology, producing the cardiac branch of
      FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mitochondrial iron dysmetabolism
    - cardiomyocyte hypertrophy
    - disrupted intercalated discs
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:28789479
      reference_title: "Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."
      explanation: Human cardiac pathology links FRDA genotype/frataxin deficiency to cardiomyocyte structural injury.
  - target: Pancreatic Beta-Cell Apoptosis
    description: >
      In pancreatic beta cells, frataxin deficiency causes mitochondrial
      dysfunction and oxidative stress-mediated intrinsic apoptosis, explaining
      the diabetes branch of FRDA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - beta-cell mitochondrial dysfunction
    - oxidative stress-mediated intrinsic apoptosis
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:25552656
      reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "pancreatic β-cell dysfunction and death cause diabetes in FRDA. This is secondary to mitochondrial dysfunction and apoptosis"
      explanation: Connects frataxin-deficient beta-cell mitochondrial dysfunction and apoptosis to diabetes.
  - target: Progressive Skeletal Deformity
    description: >
      Neurologic imbalance, sensory neuropathy, weakness, and FRDA skeletal
      involvement converge on progressive spinal and foot deformity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - proprioceptive impairment
    - progressive neuromuscular weakness
    - skeletal involvement
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This autosomal recessive disease affects central and peripheral nervous systems, heart, skeleton, and endocrine pancreas."
      explanation: Places skeletal involvement in the same multisystem FRDA pathologic spectrum as neurologic, cardiac, and pancreatic disease.
- name: Dorsal Root Ganglion Sensory Neuronopathy
  description: >
    FRDA injures dorsal root ganglion sensory neurons and their satellite-cell
    niche, causing loss of proprioceptive and vibration-sense input. This
    explains sensory neuropathy, areflexia, impaired balance, and a major
    upstream component of progressive gait and limb ataxia.
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  - preferred_term: glial cell
    term:
      id: CL:0000125
      label: glial cell
  locations:
  - preferred_term: dorsal root ganglion
    term:
      id: UBERON:0000044
      label: dorsal root ganglion
  evidence:
  - reference: PMID:27142428
    reference_title: "Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FA causes major primary changes in satellite cells and inflammatory destruction of neurons."
    explanation: Human DRG pathology supports neuron and satellite-cell injury as a proximal neuropathologic event.
  downstream:
  - target: Peripheral Neuropathy
    description: >
      DRG and sensory nerve injury produces the peripheral sensory neuropathy
      phenotype with loss of proprioception and vibration sense.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The neurological phenotype reflects lesions in dorsal root ganglia (DRG), sensory peripheral nerves, corticospinal tracts, and dentate nuclei (DN)."
      explanation: Links DRG and sensory peripheral nerve lesions to the neurologic phenotype.
  - target: Progressive Gait and Limb Ataxia
    description: >
      Loss of proprioceptive sensory input from DRG injury produces sensory
      ataxia that combines with cerebellar pathway degeneration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired proprioception
    - impaired vibration sense
    - sensory ataxia
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities, absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy."
      explanation: Connects proprioceptive/vibration loss and sensory neuropathy with gait and limb ataxia.
- name: Dentate Nucleus and Spinocerebellar Tract Degeneration
  description: >
    FRDA affects the dentate nucleus, dorsal columns, spinocerebellar tracts,
    and corticospinal tracts. Central cerebellar and spinal pathway involvement
    combines with sensory neuronopathy to drive progressive ataxia and
    dysarthria.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: dentate nucleus
    term:
      id: UBERON:0002132
      label: dentate nucleus
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Destruction of the DN, optic atrophy, and degeneration of the corticospinal tracts are intrinsic central nervous system lesions."
    explanation: Supports dentate nucleus and corticospinal tract degeneration as intrinsic CNS lesions in FRDA.
  downstream:
  - target: Progressive Gait and Limb Ataxia
    description: >
      Dentate and spinocerebellar tract degeneration add a cerebellar motor
      control deficit to the sensory ataxia branch.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
  - target: Dysarthria
    description: >
      Cerebellar and corticospinal pathway degeneration contributes to impaired
      speech motor coordination.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar motor pathway dysfunction
    - corticospinal tract degeneration
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities, absence of muscle stretch reflexes, Babinski signs, loss of joint and vibratory senses, and superimposed stocking-and-glove type sensory neuropathy."
      explanation: Identifies dysarthria among the frequent neurologic signs arising in the same lesion spectrum.
  - target: Dysphagia
    description: >
      Cerebellar and corticospinal pathway dysfunction can impair swallowing
      motor coordination, producing dysphagia as part of the classical FRDA
      neurologic phenotype.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired bulbar motor coordination
    - progressive neurologic dysfunction
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:23859346
      reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
      explanation: Lists dysphagia among the classical FRDA neurologic features.
  - target: Nystagmus
    description: >
      Central nervous system involvement in FRDA produces oculomotor disturbance,
      including nystagmus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar oculomotor pathway dysfunction
    - abnormal saccades and square wave jerks
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:21315377
      reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Many patients with FRDA have nystagmus."
      explanation: Directly supports nystagmus as an FRDA neurologic manifestation.
- name: Cardiomyocyte Mitochondrial Injury
  description: >
    In the heart, frataxin deficiency produces cardiomyocyte hypertrophy,
    iron-positive inclusions, and disrupted intercalated discs. The clinical
    downstream manifestation is hypertrophic cardiomyopathy, a major determinant
    of premature mortality in FRDA.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  locations:
  - preferred_term: myocardium
    term:
      id: UBERON:0002349
      label: myocardium
  evidence:
  - reference: PMID:28789479
    reference_title: "Heart and Nervous System Pathology in Compound Heterozygous Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microscopy showed cardiomyocyte hypertrophy, iron-positive inclusions, and disrupted intercalated discs."
    explanation: Human tissue pathology supports the cardiomyocyte injury node.
  downstream:
  - target: Hypertrophic Cardiomyopathy
    description: >
      Cardiomyocyte hypertrophy and mitochondrial injury produce the common
      hypertrophic cardiomyopathy phenotype.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:39337401
      reference_title: "Skeletal Muscle Involvement in Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most prominent manifestation is a hypertrophic cardiomyopathy, which also represents the major determinant of premature mortality."
      explanation: Links FRDA cardiac involvement specifically to hypertrophic cardiomyopathy and mortality.
- name: Pancreatic Beta-Cell Apoptosis
  description: >
    Frataxin-deficient pancreatic beta cells undergo mitochondrial dysfunction,
    oxidative stress, and intrinsic apoptosis, explaining why a subset of FRDA
    patients develop diabetes mellitus.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  locations:
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  evidence:
  - reference: PMID:25552656
    reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that β-cell demise in frataxin deficiency is the consequence of oxidative stress-mediated activation of the intrinsic pathway of apoptosis."
    explanation: Demonstrates the beta-cell apoptosis mechanism downstream of frataxin deficiency.
  downstream:
  - target: Diabetes Mellitus
    description: >
      Beta-cell dysfunction and death reduce insulin secretory capacity and
      produce the FRDA diabetes phenotype.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
    evidence:
    - reference: PMID:25552656
      reference_title: "Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We have previously demonstrated that pancreatic β-cell dysfunction and death cause diabetes in FRDA."
      explanation: Directly links pancreatic beta-cell dysfunction/death to diabetes in FRDA.
- name: Progressive Skeletal Deformity
  description: >
    FRDA skeletal involvement includes progressive scoliosis and pes cavus. The
    mechanism is represented as an indirect downstream path from the FXN
    loss-of-function multisystem disorder through neuromuscular imbalance,
    weakness, sensory neuropathy, and skeletal involvement.
  locations:
  - preferred_term: skeleton
    term:
      id: UBERON:0001434
      label: skeletal system
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scoliosis and foot deformity (pes cavus) may also be early signs and precede ataxia."
    explanation: Human clinical-pathology review supports scoliosis and pes cavus as FRDA skeletal manifestations.
  downstream:
  - target: Scoliosis
    description: >
      Progressive skeletal deformity manifests as scoliosis in the FRDA
      phenotype list.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
  - target: Pes Cavus
    description: >
      Progressive skeletal and neuromuscular involvement manifests as pes cavus
      in the FRDA phenotype list.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_fxn_loss_of_function
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fxn_loss_of_function
  hypothesis_label: Canonical FXN Loss-of-Function Mitochondrial Pathograph
  status: CANONICAL
  description: >
    Biallelic FXN intron 1 GAA repeat expansion causes epigenetic
    transcriptional silencing and frataxin deficiency. Frataxin deficiency
    impairs mitochondrial Fe-S cluster biogenesis, oxidative phosphorylation,
    and iron handling, creating tissue-selective vulnerability in dorsal root
    ganglion sensory neurons, dentate/spinal pathways, cardiomyocytes,
    pancreatic beta cells, and the skeleton.
  evidence:
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deficiency of frataxin, a small mitochondrial protein, is responsible for all clinical and morphological manifestations of FRDA."
    explanation: Establishes frataxin deficiency as the common causal mechanism underlying the multisystem FRDA phenotype.
phenotypes:
- category: Neurologic
  name: Progressive Gait and Limb Ataxia
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >
    Progressive cerebellar and sensory ataxia affecting gait and limb coordination
    is the hallmark feature. Most patients require wheelchair use within 10-15
    years of onset.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Comprehensive description of the classical Friedreich ataxia phenotype with ataxia as the core feature.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002070 | Limb ataxia | Very frequent (99-80%)"
    explanation: Orphanet's HPO table supports very frequent limb ataxia in Friedreich ataxia.
- category: Neurologic
  name: Dysarthria
  frequency: VERY_FREQUENT
  description: >
    Progressive speech difficulty due to cerebellar dysfunction, typically
    developing within a few years of disease onset.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia"
    explanation: Dysarthria is part of the classical phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Very frequent (99-80%)"
    explanation: Orphanet's HPO table supports dysarthria as a very frequent Friedreich ataxia phenotype.
- category: Musculoskeletal
  name: Muscle Weakness
  frequency: FREQUENT
  description: >
    Limb weakness, including distal extremity weakness and skeletal muscle
    involvement, is part of the classical Friedreich ataxia phenotype.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
    explanation: Lists leg weakness among the classical FRDA clinical features.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The following neurological signs are most frequent: Gait ataxia, dysmetria of arms and legs, dysarthria, head titubation, atrophy and weakness of the distal extremities"
    explanation: Identifies distal extremity weakness among the most frequent neurologic signs in FRDA.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001324 | Muscle weakness | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports muscle weakness as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Dysphagia
  frequency: OCCASIONAL
  description: >
    Swallowing impairment occurs as part of the classical neurologic phenotype
    of Friedreich ataxia.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities"
    explanation: Lists dysphagia among the classical FRDA clinical features.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Occasional (29-5%)"
    explanation: Orphanet's HPO table supports dysphagia as an occasional Friedreich ataxia phenotype.
- category: Neurologic
  name: Nystagmus
  frequency: FREQUENT
  description: >
    Nystagmus and other eye movement abnormalities occur in Friedreich ataxia.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes"
    explanation: Lists eye movement abnormalities among the classical FRDA clinical features.
  - reference: PMID:21315377
    reference_title: "Friedreich's ataxia: pathology, pathogenesis, and molecular genetics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many patients with FRDA have nystagmus."
    explanation: Directly supports nystagmus as a common FRDA neurologic manifestation.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000639 | Nystagmus | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports nystagmus as a frequent Friedreich ataxia phenotype.
- category: Neurologic
  name: Peripheral Neuropathy
  frequency: VERY_FREQUENT
  description: >
    Sensory neuropathy with loss of deep tendon reflexes (areflexia) and
    impaired proprioception and vibration sense. The dorsal root ganglia
    are preferentially affected.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
- category: Cardiac
  name: Hypertrophic Cardiomyopathy
  frequency: FREQUENT
  description: >
    Hypertrophic cardiomyopathy is present in approximately 60-75% of patients
    and is the leading cause of death. It can progress to dilated cardiomyopathy
    with heart failure.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "his description remains at the core of the classical clinical phenotype of gait and limb ataxia, poor balance and coordination, leg weakness, sensory loss, areflexia, impaired walking, dysarthria, dysphagia, eye movement abnormalities, scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Cardiomyopathy is listed as part of the classical Friedreich ataxia phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001638 | Cardiomyopathy | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports cardiomyopathy as a frequent Friedreich ataxia phenotype.
- category: Musculoskeletal
  name: Scoliosis
  frequency: FREQUENT
  description: >
    Progressive scoliosis is common, often requiring surgical intervention.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Scoliosis is part of the classical phenotype.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports scoliosis as a frequent Friedreich ataxia phenotype.
- category: Musculoskeletal
  name: Pes Cavus
  frequency: FREQUENT
  description: >
    High-arched feet (pes cavus) are a characteristic skeletal deformity.
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early-onset cases tend to have more rapid progression and a higher frequency of non-neurological features such as diabetes, cardiomyopathy, scoliosis and pes cavus."
    explanation: Pes cavus is more frequent in early-onset cases.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001761 | Pes cavus | Frequent (79-30%)"
    explanation: Orphanet's HPO table supports pes cavus as a frequent Friedreich ataxia phenotype.
- category: Endocrine
  name: Diabetes Mellitus
  frequency: OCCASIONAL
  description: >
    Diabetes mellitus occurs in approximately 10-30% of patients, likely due to
    beta cell dysfunction from mitochondrial impairment and iron toxicity.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "scoliosis, foot deformities, cardiomyopathy and diabetes."
    explanation: Diabetes is part of the classical phenotype description.
  - reference: ORPHA:95
    reference_title: "Friedreich ataxia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000819 | Diabetes mellitus | Occasional (29-5%)"
    explanation: Orphanet's HPO table supports diabetes mellitus as an occasional Friedreich ataxia phenotype.
genetic:
- name: FXN
  gene_term:
    preferred_term: FXN
    term:
      id: hgnc:3951
      label: FXN
  association: GAA Trinucleotide Repeat Expansion
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  notes: >
    Homozygous GAA repeat expansion in intron 1 of FXN on chromosome 9q21.11
    accounts for approximately 96% of cases. Normal alleles have 5-33 repeats;
    affected individuals have 66-1700 repeats. A small number of cases are
    compound heterozygous for an expansion and a point mutation or deletion.
    Repeat length inversely correlates with age of onset and frataxin levels.
  variants:
  - name: FXN intron 1 GAA repeat expansion
    description: >
      Pathogenic non-coding trinucleotide repeat expansion in intron 1 of FXN
      that silences FXN transcription. Most affected individuals are homozygous
      for expanded alleles; a minority are compound heterozygous for one
      expansion plus an FXN deletion, point mutation, or insertion.
    gene:
      preferred_term: FXN
      term:
        id: hgnc:3951
        label: FXN
    clinical_significance: PATHOGENIC
    type: trinucleotide_repeat_expansion
    functional_effects:
    - function: FXN transcription
      description: Expanded intronic GAA repeat causes reduced FXN transcription through repressive chromatin and transcriptional silencing.
      type: loss-of-expression
      regulatory_category: LOE
      regulatory_element_type: SILENCER
      regulatory_mechanism: Repressive chromatin formation around the expanded intron 1 GAA repeat.
    evidence:
    - reference: PMID:32826895
      reference_title: "Frataxin gene editing rescues Friedreich's ataxia pathology in dorsal root ganglia organoid-derived sensory neurons."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Friedreich's ataxia (FRDA) is an autosomal-recessive neurodegenerative and cardiac disorder which occurs when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron."
      explanation: Supports the variant-level functional effect of the GAA repeat expansion as FXN transcriptional silencing.
  evidence:
  - reference: PMID:14653404
    reference_title: "Friedreich ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the unstable GAA expansion that underlies FA causes a deficiency of the mitochondrial protein frataxin"
    explanation: Confirms GAA expansion as the causative mutation leading to frataxin deficiency.
  - reference: PMID:23859346
    reference_title: "Clinical features of Friedreich's ataxia: classical and atypical phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inheritance is autosomal recessive with the vast majority of cases showing an unstable intronic GAA expansion in both alleles of the frataxin gene on chromosome 9q13."
    explanation: Confirms autosomal recessive inheritance with homozygous GAA expansion in FXN.
  - reference: CGGV:assertion_ec3f674b-1e71-4254-a0f9-f8909becff59-2017-12-22T170000.000Z
    reference_title: "FXN / Friedreich ataxia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FXN | HGNC:3951 | Friedreich ataxia | MONDO:0100339 | AR | Definitive"
    explanation: ClinGen classifies the FXN-Friedreich ataxia gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Omaveloxolone
  description: >
    Approved pharmacotherapy for individuals with Friedreich ataxia aged 16
    years and older. It is used to slow neurologic progression by modulating
    oxidative-stress and mitochondrial-function pathways rather than restoring
    FXN expression directly.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: omaveloxolone
      term:
        id: CHEBI:229661
        label: omaveloxolone
  target_mechanisms:
  - target: Mitochondrial Bioenergetic Failure and Oxidative Stress
    treatment_effect: MODULATES
    description: >
      Omaveloxolone acts downstream of FXN silencing by targeting the oxidative
      stress and mitochondrial dysfunction branch of the pathograph.
    evidence:
    - reference: PMID:39115603
      reference_title: "New and Emerging Drug and Gene Therapies for Friedreich Ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Currently therapies focus on reducing oxidative stress and improving mitochondrial function, modulating frataxin controlled metabolic pathways and gene replacement and editing."
      explanation: Supports placing approved and emerging pharmacotherapies on the oxidative-stress/mitochondrial-function mechanism branch.
  evidence:
  - reference: PMID:39115603
    reference_title: "New and Emerging Drug and Gene Therapies for Friedreich Ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approval of omaveloxolone, the first treatment for individuals with FRDA aged 16 years and over, has created much excitement for both those living with FRDA and those that care for them."
    explanation: Recent review states that omaveloxolone is the first approved FRDA treatment for patients aged 16 years and older.
- name: Supportive and Symptomatic Care
  description: >
    Multidisciplinary care including physical therapy, occupational therapy,
    speech therapy, and orthopedic management of scoliosis and foot deformities.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:29053830
    reference_title: "Friedreich's ataxia: clinical features, pathogenesis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management of Freidreich's ataxia is currently focussed on symptomatic management, delivered by the multidisciplinary team."
    explanation: Confirms that current management is multidisciplinary and symptomatic.
- name: Cardiac Management
  description: >
    Regular cardiac monitoring and treatment of cardiomyopathy and arrhythmias.
    ACE inhibitors and beta-blockers may be used for heart failure management.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Investigational Frataxin-Restoring Therapies
  description: >
    Clinical trials are investigating agents that address the aberrant silencing
    of the frataxin gene, including histone deacetylase inhibitors, gene therapy
    approaches, and frataxin replacement strategies.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:29053830
    reference_title: "Friedreich's ataxia: clinical features, pathogenesis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phase II clinical trials in agents that address the abberrant silencing of the frataxin gene need to be translated into large placebo-controlled Phase III trials to help establish their therapeutic potential."
    explanation: Confirms ongoing clinical development of frataxin-restoring therapies.
- name: Genetic Counseling
  description: >
    Genetic counseling for autosomal recessive inheritance pattern and carrier
    testing for family members.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
clinical_trials:
- name: NCT02255435
  phase: PHASE_II
  status: COMPLETED
  description: >
    Completed phase 2 MOXIe trial of RTA 408, also known as omaveloxolone,
    evaluating safety, pharmacodynamics, cycling work, and 48-week modified
    Friedreich's Ataxia Rating Scale change in Friedreich ataxia.
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  - preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: clinicaltrials:NCT02255435
    reference_title: "A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work."
    explanation: ClinicalTrials.gov record documents the completed omaveloxolone MOXIe trial and its neurologic functional endpoints in FRDA.
datasets:
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 59 citations 2026-04-25T22:28:55.674992

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Friedreich Ataxia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Friedreich Ataxia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Friedreich Ataxia (FRDA) — Comprehensive Disease Characteristics Research Report (2023–2024 prioritized)

Executive summary

Friedreich ataxia (FRDA) is a life-shortening, autosomal recessive multisystem neurodegenerative disorder primarily caused by biallelic GAA trinucleotide repeat expansions in intron 1 of FXN (frataxin), resulting in transcriptional silencing and frataxin deficiency. Frataxin deficiency disrupts mitochondrial iron–sulfur (Fe–S) cluster biogenesis and mitochondrial function, leading to selective vulnerability of dorsal root ganglia (DRG) sensory neurons, spinal cord tracts, cerebellar dentate nucleus, and cardiomyocytes. Natural history studies (notably FA-COMS/FACOMS) show progressive neurologic decline with ambulation loss typically within ~15 years, with faster progression in earlier-onset disease. In February 2023, omaveloxolone (Skyclarys™), an Nrf2 pathway activator, became the first approved therapy; a propensity-score matched analysis comparing the MOXIe extension to FACOMS natural history data suggests ~55% slowing of mFARS progression over 3 years. (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2, rummey2022naturalhistoryof pages 3-5, lynch2024propensitymatchedcomparison pages 1-2)

1. Disease information

1.1 What is the disease?

FRDA is described as an autosomal recessive inherited ataxia with progressive neurologic dysfunction (gait/limb ataxia, dysarthria, areflexia, sensory loss) and systemic involvement including cardiomyopathy, skeletal deformities (e.g., scoliosis, pes cavus), and diabetes/metabolic dysfunction. (scott2024newandemerging pages 1-2, lima2025earlyexperienceon pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

Abstract-supported definition (direct quote): Park et al. (2025) describe FRDA as an “autosomal recessive neurodegenerative disorder characterized by ataxia, sensory loss and pyramidal signs.” (park2025longreadsequencingidentifies pages 1-2)

1.2 Key identifiers

  • MONDO: MONDO_0100339 (Open Targets disease entity for Friedreich ataxia). URL: https://platform.opentargets.org/disease/MONDO_0100339 (scott2024newandemerging pages 1-2)
  • OMIM / Orphanet / ICD-10/ICD-11 / MeSH: These identifiers were not explicitly present in the full-text sources retrieved in this run; therefore they cannot be cited from primary evidence here.

1.3 Synonyms and alternative names

Commonly used variants in the literature include “Friedreich’s ataxia” and “Friedreich ataxia (FRDA/FA)”. (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

1.4 Evidence source type

Most disease-defining statements in this report are derived from: * Aggregated disease-level resources: reviews and systematic reviews (e.g., CNS Drugs 2024; IJMS 2024). (scott2024newandemerging pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2) * Human clinical cohorts/natural history studies: FACOMS/FA-COMS. (rummey2022naturalhistoryof pages 3-5, rummey2020predictorsofloss pages 1-2) * Human neuropathology: DRG and dentate nucleus tissue analyses. (koeppen2016dorsalrootganglia pages 1-2, koeppen2012friedreichsataxiacauses pages 1-2) * Model organism/cellular models: conditional mice, repeat-expansion mice, iPSC-derived models. (mercadoayon2022cerebellarpathologyin pages 1-2, mazzara2020frataxingeneediting pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause (genetic): * ~96% of FRDA cases are homozygous for expanded GAA repeats in intron 1 of FXN, typically reported as ~56–1300 repeats. (scott2024newandemerging pages 1-2) * A minority (~4%) are compound heterozygotes, with a GAA expansion on one allele and a pathogenic small variant or deletion on the other. (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

Mechanistic cause: expanded repeats induce locus-specific epigenetic changes and transcriptional silencing of FXN, resulting in low frataxin. (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

2.2 Risk factors

  • Genotype severity: longer GAA expansions correlate with earlier onset and faster progression (a key genetic severity determinant). (indelicato2024skeletalmuscleinvolvement pages 1-2, rummey2022naturalhistoryof pages 2-3)
  • Age at onset: earlier onset groups show faster mFARS progression in FACOMS. (rummey2022naturalhistoryof pages 3-5)

Environmental risk factors as disease initiators are not established for this Mendelian condition in the sources retrieved here.

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No direct gene–environment interaction evidence was identified in the retrieved sources.

3. Phenotypes

3.1 Core neurologic phenotypes

Common neurologic phenotype includes progressive gait and limb ataxia, dysarthria, areflexia, sensory loss (proprioception/vibration), and pyramidal signs. (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2, lima2025earlyexperienceon pages 1-2)

Suggested HPO terms (non-exhaustive; ontology IDs not cited from sources): * Ataxia; Gait ataxia; Limb ataxia * Dysarthria * Areflexia * Loss of proprioception / impaired vibration sense * Babinski sign / pyramidal signs

3.2 Non-neurologic/systemic phenotypes

  • Cardiomyopathy (often hypertrophic) is a major determinant of premature mortality. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
  • Scoliosis and pes cavus are frequently described. (lima2025earlyexperienceon pages 1-2)
  • Diabetes occurs in a subset (systematic review notes 10–30%). (jain2022clinicalevidenceof pages 2-3)

Suggested HPO terms (examples): * Hypertrophic cardiomyopathy * Scoliosis * Pes cavus * Diabetes mellitus

3.3 Age of onset, severity, progression, frequency

  • Typical symptom onset: average ~10–15 years. (scott2024newandemerging pages 1-2)
  • Wheelchair dependence: typical-onset patients become wheelchair dependent ~11.5 years after onset (reported in review; FACOMS-aligned). (scott2024newandemerging pages 1-2)
  • Disease progression: progressive; rates vary strongly by age at onset and ambulation status. (rummey2022naturalhistoryof pages 3-5)

3.4 Quality of life impact

Clinical decline impacts ambulation and upright stability, with loss of ambulation as a meaningful functional endpoint. (rummey2020predictorsofloss pages 1-2)

4. Genetic/molecular information

4.1 Causal gene(s)

  • Primary causal gene: FXN (frataxin). (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)

4.2 Pathogenic variants

  • Repeat expansion: GAA trinucleotide repeat expansion in intron 1 of FXN. Normal alleles reported as 5–35 repeats; disease-causing typically >66; many affected individuals carry >600, with upper ranges reported up to ~1700. (park2025longreadsequencingidentifies pages 1-2)
  • Compound heterozygosity: GAA expansion + pathogenic small variant/deletion (~4% of cases). (park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2)
  • Somatic instability/interruptions: complex repeat interruptions and mosaicism can complicate detection; long-read genome sequencing can resolve complex expansions. (park2025longreadsequencingidentifies pages 1-2)

Abstract-supported mechanism (direct quote): Mazzara et al. (2020) state FRDA occurs “when transcription of the FXN gene is silenced due to an excessive expansion of GAA repeats into its first intron.” (mazzara2020frataxingeneediting pages 1-2)

4.3 Functional consequences

Frataxin deficiency leads to impaired Fe–S cluster biosynthesis and mitochondrial dysfunction with downstream oxidative stress and iron dysregulation. (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3)

4.4 Modifier genes / epigenetics

  • Epigenetic silencing: GAA expansions induce locus-specific epigenetic changes (including upstream hypermethylation and downstream hypomethylation signatures) that contribute to transcriptional silencing. (park2025longreadsequencingidentifies pages 1-2)
  • DNA repair/chromatin cross-talk as a repeat instability mechanism (2024 development): Lai et al. (2024) report temozolomide-induced and H3K9 methyltransferase inhibitor-induced GAA repeat contraction in neural cells with increased frataxin protein, proposing crosstalk between chromatin opening (H3K9 methylation inhibition) and base excision repair. (scott2024newandemerging pages 1-2)

Suggested ontology terms (examples): * GO (process): iron–sulfur cluster assembly; mitochondrial ATP synthesis; response to oxidative stress; DNA repair; chromatin organization.

5. Environmental information

FRDA is primarily genetic. Environmental contributors, infectious triggers, or lifestyle causes were not supported as primary etiologic drivers in the retrieved sources.

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

  1. Biallelic FXN GAA expansion → 2. Repressive chromatin / transcriptional silencing → 3. Frataxin deficiency → 4. Impaired Fe–S cluster biogenesis and mitochondrial dysfunction → 5. Oxidative stress/iron dysregulation, ETC defects, cellular injury → 6. Selective degeneration of DRG/spinal cord/dentate nucleus + cardiomyocyte dysfunction → 7. Progressive neurologic disability + cardiomyopathy-related morbidity/mortality. (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3, koeppen2016dorsalrootganglia pages 1-2)

6.2 Selective vulnerability and primary tissues

Despite broad frataxin expression, pathology is tissue-selective, prominently affecting DRG sensory neurons and the cerebellar dentate nucleus, with major cardiac involvement. (indelicato2024skeletalmuscleinvolvement pages 1-2, koeppen2012friedreichsataxiacauses pages 1-2)

6.3 Cellular processes and neuropathology (human evidence)

DRG (human tissue): Koeppen et al. (2016) show DRG pathology includes satellite cell proliferation into multiple perineuronal layers, connexin-43 gap junction upregulation, monocyte infiltration, and ferritin upregulation in satellite cells/monocytes consistent with inflammatory and iron-handling changes. (koeppen2016dorsalrootganglia pages 1-2)

Dentate nucleus (human tissue metal mapping): Koeppen et al. (2012) report that maximal Fe/Cu/Zn concentrations did not differ between FRDA and controls, but metal redistribution occurs with structural collapse of the dentate nucleus and increased ferritin-positive microglia; reported mean Fe 364±117 vs 344±159 µg/mL (controls vs FRDA) in PEG/DMSO-embedded tissue. (koeppen2012friedreichsataxiacauses pages 1-2)

6.4 Mitochondrial dysfunction in DRG (2024 mechanistic development)

Sanz-Alcázar et al. (2024) report frataxin deficiency in DRG neuron cultures and DRG tissue from an FXN mouse model causes reduced ETC complex I/II activity and levels, altered mitochondrial morphology, reduced NAD+/NADH ratio, impaired sirtuin activity (SirT3) and increased acetylation of SOD2 (with increased mitochondrial superoxide); honokiol (SirT3 activator) restored respiration and reduced oxidative markers. (sanzalcazar2024mitochondrialimpairmentdecreased pages 1-2)

Suggested ontology terms: * CL (cell types): dorsal root ganglion sensory neuron; satellite glial cell; microglia/monocyte lineage; cardiomyocyte. * GO-CC (compartments): mitochondrion; mitochondrial inner membrane.

7. Anatomical structures affected

7.1 Organ/system level

  • Nervous system: peripheral sensory system (DRG, dorsal roots), spinal cord tracts, cerebellar dentate nucleus, corticospinal tracts. (koeppen2016dorsalrootganglia pages 1-2, koeppen2013friedreichataxianeuropathology pages 1-1)
  • Heart: cardiomyopathy is prominent and contributes to mortality risk. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
  • Muscle: skeletal muscle involvement contributes to fatigue/weakness, and restrictive respiratory impairment can occur. (indelicato2024skeletalmuscleinvolvement pages 1-2)

7.2 Tissue/cell level

  • DRG neuronal loss and accompanying satellite cell/inflammatory changes (human). (koeppen2016dorsalrootganglia pages 1-2)
  • Dentate nucleus neuronal atrophy and microglial ferritin positivity (human). (koeppen2012friedreichsataxiacauses pages 1-2)

Suggested UBERON examples (names only): dorsal root ganglion; spinal cord; cerebellar dentate nucleus; myocardium.

8. Temporal development

8.1 Onset

  • Mean onset ~10–15 years in typical FRDA. (scott2024newandemerging pages 1-2)
  • Late-onset forms are recognized (e.g., after age 25 or 40). (lima2025earlyexperienceon pages 1-2)

8.2 Progression and staging

FACOMS natural history (key statistics): * 1,115 participants and 5,287 yearly visits. (rummey2022naturalhistoryof pages 1-2) * Median follow-up ~5 years (IQR ~3–10). (rummey2022naturalhistoryof pages 2-3) * Annual ambulatory mFARS progression differs by onset group: early-onset ~2.62 points/year vs typical-onset ~1.83 points/year; intermediate ~1.24 points/year; late ~1.18 points/year (approximate as reported with CIs). (rummey2022naturalhistoryof pages 3-5) * Ambulatory decline is driven primarily by the Upright Stability Score (USS) component of mFARS. (rummey2022naturalhistoryof pages 1-2)

Loss of ambulation: In a large FA-COMS analysis (n≈1021), early-onset patients had a median of 11.5 years from symptom onset to full wheelchair dependence (FDS=5). (rummey2020predictorsofloss pages 1-2)

9. Inheritance and population

9.1 Epidemiology

A contemporary review reports FRDA affects ~1:40,000 (predominantly European populations) and is about ~1 in 50,000 Europeans in another systematic review/meta-analysis context. (scott2024newandemerging pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)

9.2 Inheritance pattern

Autosomal recessive inheritance is consistently reported. (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2)

9.3 Carrier status

Carriers of one expanded allele are asymptomatic in the cited review and have residual frataxin ~40–68% of normal (vs 4–29% in affected individuals). (scott2024newandemerging pages 1-2)

10. Diagnostics

10.1 Genetic testing (repeat expansion and sequencing)

  • Standard diagnostic approach depends on detecting FXN intron 1 GAA expansions; molecular diagnosis has been possible since 1996. (scott2024newandemerging pages 1-2)
  • Long-read sequencing can resolve complex/interruptions/mosaic expansions that may be missed by conventional repeat-primed or long-range PCR assays; Park et al. (2025) highlight that interruptions and somatic instability “complicate molecular diagnosis” and that long-read genome sequencing can detect large expansions and mosaic variation. (park2025longreadsequencingidentifies pages 1-2)

10.2 Biomarkers and imaging

A 2024 biomarker systematic review/meta-analysis found only modest pooled improvements in combined FARS/mFARS with mitochondrial-function drugs and reported LV mass index (LVMI) improvement for some interventions, but overall evidence quality was low and the “optimal biomarker…has yet to be identified.” (gavriilaki2024therapeuticbiomarkersin pages 1-2)

Neuroimaging biomarkers (MRI/QSM/MRS) are a focus of contemporary FRDA trial design and natural-history imaging studies. (scott2024newandemerging pages 3-5)

11. Outcome / prognosis

  • Mean survival ≈39 years (review) and reduced life expectancy is commonly attributed to cardiac complications. (scott2024newandemerging pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)
  • Cardiomyopathy is repeatedly emphasized as a major determinant of survival. (indelicato2024skeletalmuscleinvolvement pages 1-2, gavriilaki2024therapeuticbiomarkersin pages 1-2)

12. Treatment

12.1 Approved pharmacotherapy: Omaveloxolone (Skyclarys™)

Regulatory status: FDA approval February 2023 for patients aged ≥16 years; EC approval February 2024. (scott2024newandemerging pages 3-5)

Efficacy (trial + external comparator): A propensity-score matched comparison of MOXIe extension (omaveloxolone-treated) vs FACOMS natural history controls reported: * At Year 3, matched FACOMS progressed 6.61 mFARS points vs 3.00 points in MOXIe extension; difference 3.61 points; nominal p=0.0001. (lynch2024propensitymatchedcomparison pages 7-8) * This corresponds to ~55% slowing of mFARS progression. (lynch2024propensitymatchedcomparison pages 1-2, scott2024newandemerging pages 3-5)

Visual evidence (trial outcome trajectories): Figure 3 and Table 5 from Lynch et al. (2024) summarize the 3-year separation in mFARS trajectories and the Year-3 difference used in the main result. (lynch2024propensitymatchedcomparison media 7250a862, lynch2024propensitymatchedcomparison media d049e362)

Safety and real-world implementation: Expert guidance and post-approval experience emphasize that aminotransferase elevations are common and usually transient and asymptomatic: * In the MOXIe program, ALT increases occurred in ~37% and AST in ~22% of treated patients (placebo ~2%); >3× ULN ALT/AST elevations ~31%, >5× ULN ~16%, >10× ULN ~4%; no Hy’s law cases. (perlman2025managingaminotransferaseelevations pages 7-9) * Label- and expert-opinion monitoring: baseline ALT/AST/total bilirubin; monitor monthly for first 3 months; reduce frequency thereafter if stable; temporarily discontinue if >5× ULN or >3× ULN with liver dysfunction; consider conservative interruption at ≥3× ULN even without dysfunction in real-world settings; reinitiate with stepwise titration (e.g., 50→100→150 mg) and q2-week labs for ~3 months. (perlman2025managingaminotransferaseelevations pages 1-3, perlman2025managingaminotransferaseelevations pages 11-14)

Real-world observational data: a single-center cohort (n=20; ~24 weeks) reported no discontinuations and transient asymptomatic transaminase elevations (ALT 45%); mFARS mean changed from 59.1 to 60.5 over 24 weeks (P=0.15). (lima2025earlyexperienceon pages 4-5)

Suggested MAXO terms (names only): pharmacotherapy; liver function monitoring; dose adjustment; treatment interruption/rechallenge; rehabilitation therapy.

12.2 Supportive/rehabilitative care

Multidisciplinary, symptomatic management remains central (mobility aids, therapy, cardiology and endocrinology management). (osaki2026fromgeneticmutation pages 11-12)

12.3 Experimental / emerging therapies (2024 focus)

A 2024 therapeutic landscape review emphasizes development across: * oxidative stress/mitochondrial function modulators, * frataxin-controlled metabolic pathway modulation, * gene replacement/editing approaches. (scott2024newandemerging pages 3-5)

Active or recent clinical trials (ClinicalTrials.gov): * Omaveloxolone pivotal trial: NCT02255435 (completed). (scott2024newandemerging pages 1-2) * Pediatric omaveloxolone trials: NCT06953583 (BRAVE; Phase 3), NCT06054893 (PK/safety, ages 2–15). (clinical-trials tool output) * Gene therapy for FRDA cardiomyopathy: NCT05302271 (AAVrh.10hFXN), NCT05445323, NCT07180355. (clinical-trials tool output) * Post-marketing/real-world safety follow-up: NCT06623890 (observational, 300 participants). (clinical-trials tool output)

13. Prevention

No primary prevention exists for a Mendelian recessive disorder aside from reproductive options and family-based risk management. Formal guideline statements were not retrieved in this run.

Applicable prevention concepts (knowledge-base oriented): * Carrier testing / cascade testing in families with known FXN expansions. * Genetic counseling.

14. Other species / natural disease

No naturally occurring FRDA-equivalent disease in non-human species was identified in the retrieved evidence.

15. Model organisms

FRDA modeling requires balancing genetic fidelity (GAA repeat silencing/instability) vs phenotype severity.

15.1 Mouse models

  • Conditional Cre-based models: MCK-driven cardiac/skeletal muscle knockouts model cardiomyopathy with early death; Pvalb-driven models target proprioceptive/cerebellar systems and yield severe, rapid neurologic disease. (bouchard2023findinganappropriate pages 1-2, pandolfo2025friedreichataxia pages 5-6)
  • Repeat-expansion and humanized models: KIKO and YG8 lines capture the repeat biology and epigenetic silencing context, with YG8–800 producing stronger ataxic phenotypes and repeat instability. (pandolfo2025friedreichataxia pages 5-6, bouchard2023findinganappropriate pages 1-2)
  • Inducible knockdown: FRDAkd (doxycycline-inducible) partially recapitulates DRG neuronal loss, cardiomyopathy, and ataxia; shows dentate nucleus and Purkinje neuron loss and synaptic marker declines; AAV8 frataxin restoration partially rescues synaptic markers. (mercadoayon2022cerebellarpathologyin pages 1-2)

15.2 Human cellular/iPSC models

  • DRG organoids (iPSC-derived): show DRG-like transcriptional signatures and peripheral sensory neuronal/glial subtypes; FRDA deficits are rescued by removing the entire FXN intron 1 (not just the GAA tract), implicating flanking repressed chromatin in silencing. (mazzara2020frataxingeneediting pages 1-2)

Embedded structured summary

Item Value Notes Source (include URL if available)
Disease title Friedreich ataxia: key identifiers and genetics Mendelian inherited ataxia; disease-level aggregated knowledge. https://doi.org/10.1007/s40263-024-01113-z
MONDO ID MONDO_0100339 Disease association returned by Open Targets for Friedreich ataxia (scott2024newandemerging pages 1-2). https://platform.opentargets.org/disease/MONDO_0100339
Inheritance Autosomal recessive Consistently described as autosomal recessive in recent reviews and diagnostic literature (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2). https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969
Causal gene FXN (frataxin) FXN encodes frataxin, a nuclear-encoded mitochondrial protein required for iron-sulfur cluster biogenesis (park2025longreadsequencingidentifies pages 1-2, osaki2026fromgeneticmutation pages 1-3). https://doi.org/10.3390/ijms26114969 ; https://doi.org/10.20944/preprints202604.1108.v1
Primary pathogenic variant Biallelic GAA trinucleotide repeat expansion in intron 1 of FXN Normal alleles: 5–35 repeats; disease-causing: >66 repeats; many affected individuals carry ~56–1300+ repeats, often >600 in typical disease; expansion causes transcriptional silencing and reduced FXN expression (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2). https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969
Percent of cases ~96% homozygous GAA expansion; ~4% compound heterozygous Minority of patients carry one GAA expansion plus a pathogenic small variant or deletion in FXN (scott2024newandemerging pages 1-2, park2025longreadsequencingidentifies pages 1-2, indelicato2024skeletalmuscleinvolvement pages 1-2). https://doi.org/10.1007/s40263-024-01113-z ; https://doi.org/10.3390/ijms26114969 ; https://doi.org/10.3390/ijms25189915
Frataxin levels Affected individuals: ~4–29% of normal; carriers: ~40–68% of normal Residual frataxin tracks with genotype severity; carriers are typically asymptomatic despite reduced protein levels (scott2024newandemerging pages 1-2). https://doi.org/10.1007/s40263-024-01113-z
Major affected tissues Dorsal root ganglia (DRG), dentate nucleus of cerebellum, spinal cord pathways, cardiomyocytes Tissue vulnerability is selective despite broad FXN expression; neurologic and cardiac involvement drive major morbidity and mortality (indelicato2024skeletalmuscleinvolvement pages 1-2, osaki2026fromgeneticmutation pages 1-3). https://doi.org/10.3390/ijms25189915 ; https://doi.org/10.20944/preprints202604.1108.v1

Table: This table summarizes the core identifiers, inheritance, causal gene, variant class, case distribution, frataxin levels, and major affected tissues for Friedreich ataxia. It is useful as a compact knowledge-base seed for disease definition and molecular annotation.

Notes on evidence gaps

  • OMIM/Orphanet/ICD/MeSH identifiers were not present in retrieved papers during this run; therefore they are not provided with citations.
  • Many ontology IDs (HPO/GO/CL/UBERON/MAXO) are suggested by term name to support knowledge-base construction, but the sources retrieved here did not explicitly list ontology identifiers.

Key cited sources (with dates and URLs)

  • Scott V et al. CNS Drugs. Aug 2024. https://doi.org/10.1007/s40263-024-01113-z (scott2024newandemerging pages 1-2, scott2024newandemerging pages 3-5)
  • Lynch DR et al. Ann Clin Transl Neurol. Sep 2024. https://doi.org/10.1002/acn3.51897 (lynch2024propensitymatchedcomparison pages 1-2, lynch2024propensitymatchedcomparison pages 7-8, lynch2024propensitymatchedcomparison pages 8-10)
  • Indelicato E et al. Int J Mol Sci. Sep 2024. https://doi.org/10.3390/ijms25189915 (indelicato2024skeletalmuscleinvolvement pages 1-2)
  • Gavriilaki M et al. Cerebellum. Oct 2024. https://doi.org/10.1007/s12311-023-01621-6 (gavriilaki2024therapeuticbiomarkersin pages 1-2)
  • Perlman S et al. Neurol Ther. Jun 2025. https://doi.org/10.1007/s40120-025-00752-8 (perlman2025managingaminotransferaseelevations pages 7-9, perlman2025managingaminotransferaseelevations pages 11-14)
  • Park J et al. Int J Mol Sci. May 2025. https://doi.org/10.3390/ijms26114969 (park2025longreadsequencingidentifies pages 1-2)
  • Rummey C et al. Neurology. Oct 2022. https://doi.org/10.1212/WNL.0000000000200913 (rummey2022naturalhistoryof pages 1-2, rummey2022naturalhistoryof pages 3-5)
  • Rummey C et al. EClinicalMedicine. Jan 2020. https://doi.org/10.1016/j.eclinm.2019.11.006 (rummey2020predictorsofloss pages 1-2)
  • Koeppen AH et al. Acta Neuropathol Commun. May 2016. https://doi.org/10.1186/s40478-016-0288-5 (koeppen2016dorsalrootganglia pages 1-2)
  • Koeppen AH et al. Cerebellum. May 2012. https://doi.org/10.1007/s12311-012-0383-5 (koeppen2012friedreichsataxiacauses pages 1-2)

References

  1. (scott2024newandemerging pages 1-2): Varlli Scott, Martin B. Delatycki, Geneieve Tai, and Louise A. Corben. New and emerging drug and gene therapies for friedreich ataxia. CNS Drugs, 38:791-805, Aug 2024. URL: https://doi.org/10.1007/s40263-024-01113-z, doi:10.1007/s40263-024-01113-z. This article has 15 citations and is from a peer-reviewed journal.

  2. (indelicato2024skeletalmuscleinvolvement pages 1-2): Elisabetta Indelicato, Julia Wanschitz, Wolfgang Löscher, and Sylvia Boesch. Skeletal muscle involvement in friedreich ataxia. International Journal of Molecular Sciences, 25:9915, Sep 2024. URL: https://doi.org/10.3390/ijms25189915, doi:10.3390/ijms25189915. This article has 4 citations.

  3. (rummey2022naturalhistoryof pages 3-5): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.

  4. (lynch2024propensitymatchedcomparison pages 1-2): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.

  5. (lima2025earlyexperienceon pages 1-2): Salvatore Maria Lima, Marta Caltagirone, Christian Messina, Umberto Quartetti, Nicasio Rini, Flora D’Amico, Filippo Brighina, and Vincenzo Di Stefano. Early experience on omaveloxolone in adult patients with friedreich’s ataxia: a real-world observational study. Journal of Neurology, Nov 2025. URL: https://doi.org/10.1007/s00415-025-13487-1, doi:10.1007/s00415-025-13487-1. This article has 1 citations and is from a domain leading peer-reviewed journal.

  6. (park2025longreadsequencingidentifies pages 1-2): Joohyun Park, Claudia Dufke, Zofia Fleszar, Michael Schlotterbek, Elena Buena-Atienza, Lara G. Stühn, Caspar Gross, Marc Sturm, Stephan Ossowski, Ludger Schöls, Olaf Riess, and Tobias B. Haack. Long-read sequencing identifies mosaic sequence variations in friedreich’s ataxia-gaa repeats. International Journal of Molecular Sciences, 26:4969, May 2025. URL: https://doi.org/10.3390/ijms26114969, doi:10.3390/ijms26114969. This article has 2 citations.

  7. (rummey2020predictorsofloss pages 1-2): Christian Rummey, Jennifer M. Farmer, and David R. Lynch. Predictors of loss of ambulation in friedreich's ataxia. EClinicalMedicine, 18:100213, Jan 2020. URL: https://doi.org/10.1016/j.eclinm.2019.11.006, doi:10.1016/j.eclinm.2019.11.006. This article has 68 citations and is from a peer-reviewed journal.

  8. (koeppen2016dorsalrootganglia pages 1-2): Arnulf H. Koeppen, R. Liane Ramirez, Alyssa B. Becker, and Joseph E. Mazurkiewicz. Dorsal root ganglia in friedreich ataxia: satellite cell proliferation and inflammation. Acta Neuropathologica Communications, May 2016. URL: https://doi.org/10.1186/s40478-016-0288-5, doi:10.1186/s40478-016-0288-5. This article has 77 citations and is from a peer-reviewed journal.

  9. (koeppen2012friedreichsataxiacauses pages 1-2): Arnulf H. Koeppen, R. Liane Ramirez, Devin Yu, Sarah E. Collins, Jiang Qian, Patrick J. Parsons, Karl X. Yang, Zewu Chen, Joseph E. Mazurkiewicz, and Paul J. Feustel. Friedreich's ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus. The Cerebellum, 11:845-860, May 2012. URL: https://doi.org/10.1007/s12311-012-0383-5, doi:10.1007/s12311-012-0383-5. This article has 95 citations.

  10. (mercadoayon2022cerebellarpathologyin pages 1-2): Elizabeth Mercado-Ayón, Nathan Warren, Sarah Halawani, Layne N. Rodden, Lucie Ngaba, Yi Na Dong, Joshua C. Chang, Carlos Fonck, Fulvio Mavilio, David R. Lynch, and Hong Lin. Cerebellar pathology in an inducible mouse model of friedreich ataxia. Frontiers in Neuroscience, Mar 2022. URL: https://doi.org/10.3389/fnins.2022.819569, doi:10.3389/fnins.2022.819569. This article has 17 citations and is from a peer-reviewed journal.

  11. (mazzara2020frataxingeneediting pages 1-2): Pietro Giuseppe Mazzara, Sharon Muggeo, Mirko Luoni, Luca Massimino, Mattia Zaghi, Parisa Tajalli-Tehrani Valverde, Simone Brusco, Matteo Jacopo Marzi, Cecilia Palma, Gaia Colasante, Angelo Iannielli, Marianna Paulis, Chiara Cordiglieri, Serena Gea Giannelli, Paola Podini, Cinzia Gellera, Franco Taroni, Francesco Nicassio, Marco Rasponi, and Vania Broccoli. Frataxin gene editing rescues friedreich’s ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nature Communications, Aug 2020. URL: https://doi.org/10.1038/s41467-020-17954-3, doi:10.1038/s41467-020-17954-3. This article has 102 citations and is from a highest quality peer-reviewed journal.

  12. (rummey2022naturalhistoryof pages 2-3): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.

  13. (gavriilaki2024therapeuticbiomarkersin pages 1-2): Maria Gavriilaki, Evangelia Chatzikyriakou, Maria Moschou, Marianthi Arnaoutoglou, Ioanna Sakellari, and Vasilios K. Kimiskidis. Therapeutic biomarkers in friedreich’s ataxia: a systematic review and meta-analysis. Cerebellum (London, England), 23:1184-1203, Oct 2024. URL: https://doi.org/10.1007/s12311-023-01621-6, doi:10.1007/s12311-023-01621-6. This article has 15 citations.

  14. (jain2022clinicalevidenceof pages 2-3): Paridhi Jain, Lohit Badgujar, Jelle Spoorendonk, and Katharina Buesch. Clinical evidence of interventions assessed in friedreich ataxia: a systematic review. Therapeutic Advances in Rare Disease, Jan 2022. URL: https://doi.org/10.1177/26330040221139872, doi:10.1177/26330040221139872. This article has 13 citations.

  15. (osaki2026fromgeneticmutation pages 1-3): Yuta Osaki, Umme Sabrina Haque, and Toshifumi Yokota. From genetic mutation to therapy in friedreich ataxia: molecular mechanisms, therapeutic advances, and translational challenges. Unknown journal, Apr 2026. URL: https://doi.org/10.20944/preprints202604.1108.v1, doi:10.20944/preprints202604.1108.v1.

  16. (sanzalcazar2024mitochondrialimpairmentdecreased pages 1-2): Arabela Sanz-Alcázar, Elena Britti, Fabien Delaspre, Marta Medina-Carbonero, Maria Pazos-Gil, Jordi Tamarit, Joaquim Ros, and Elisa Cabiscol. Mitochondrial impairment, decreased sirtuin activity and protein acetylation in dorsal root ganglia in friedreich ataxia models. Cellular and Molecular Life Sciences: CMLS, Dec 2024. URL: https://doi.org/10.1007/s00018-023-05064-4, doi:10.1007/s00018-023-05064-4. This article has 20 citations.

  17. (koeppen2013friedreichataxianeuropathology pages 1-1): Arnulf H. Koeppen and Joseph E. Mazurkiewicz. Friedreich ataxia: neuropathology revised. Journal of neuropathology and experimental neurology, 72 2:78-90, Feb 2013. URL: https://doi.org/10.1097/nen.0b013e31827e5762, doi:10.1097/nen.0b013e31827e5762. This article has 313 citations and is from a peer-reviewed journal.

  18. (rummey2022naturalhistoryof pages 1-2): Christian Rummey, Louise A. Corben, Martin Delatycki, George Wilmot, Sub H. Subramony, Manuela Corti, Khalaf Bushara, Antoine Duquette, Christopher Gomez, J. Chad Hoyle, Richard Roxburgh, Lauren Seeberger, Grace Yoon, Katherine Mathews, Theresa Zesiewicz, Susan Perlman, and David R. Lynch. Natural history of friedreich ataxia. Neurology, Oct 2022. URL: https://doi.org/10.1212/wnl.0000000000200913, doi:10.1212/wnl.0000000000200913. This article has 74 citations and is from a highest quality peer-reviewed journal.

  19. (scott2024newandemerging pages 3-5): Varlli Scott, Martin B. Delatycki, Geneieve Tai, and Louise A. Corben. New and emerging drug and gene therapies for friedreich ataxia. CNS Drugs, 38:791-805, Aug 2024. URL: https://doi.org/10.1007/s40263-024-01113-z, doi:10.1007/s40263-024-01113-z. This article has 15 citations and is from a peer-reviewed journal.

  20. (lynch2024propensitymatchedcomparison pages 7-8): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.

  21. (lynch2024propensitymatchedcomparison media 7250a862): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.

  22. (lynch2024propensitymatchedcomparison media d049e362): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.

  23. (perlman2025managingaminotransferaseelevations pages 7-9): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.

  24. (perlman2025managingaminotransferaseelevations pages 1-3): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.

  25. (perlman2025managingaminotransferaseelevations pages 11-14): Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, and David R. Lynch. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurology and Therapy, 14:1209-1227, Jun 2025. URL: https://doi.org/10.1007/s40120-025-00752-8, doi:10.1007/s40120-025-00752-8. This article has 8 citations and is from a domain leading peer-reviewed journal.

  26. (lima2025earlyexperienceon pages 4-5): Salvatore Maria Lima, Marta Caltagirone, Christian Messina, Umberto Quartetti, Nicasio Rini, Flora D’Amico, Filippo Brighina, and Vincenzo Di Stefano. Early experience on omaveloxolone in adult patients with friedreich’s ataxia: a real-world observational study. Journal of Neurology, Nov 2025. URL: https://doi.org/10.1007/s00415-025-13487-1, doi:10.1007/s00415-025-13487-1. This article has 1 citations and is from a domain leading peer-reviewed journal.

  27. (osaki2026fromgeneticmutation pages 11-12): Yuta Osaki, Umme Sabrina Haque, and Toshifumi Yokota. From genetic mutation to therapy in friedreich ataxia: molecular mechanisms, therapeutic advances, and translational challenges. Unknown journal, Apr 2026. URL: https://doi.org/10.20944/preprints202604.1108.v1, doi:10.20944/preprints202604.1108.v1.

  28. (bouchard2023findinganappropriate pages 1-2): Camille Bouchard, Catherine Gérard, Solange Gni-fiene Yanyabé, Nathalie Majeau, Malek Aloui, Gabrielle Buisson, Pouiré Yameogo, Vanessa Couture, and Jacques P. Tremblay. Finding an appropriate mouse model to study the impact of a treatment for friedreich ataxia on the behavioral phenotype. Genes, 14:1654, Aug 2023. URL: https://doi.org/10.3390/genes14081654, doi:10.3390/genes14081654. This article has 8 citations.

  29. (pandolfo2025friedreichataxia pages 5-6): Massimo Pandolfo. Friedreich ataxia. Neurology Genetics, Feb 2025. URL: https://doi.org/10.1212/nxg.0000000000200236, doi:10.1212/nxg.0000000000200236. This article has 6 citations.

  30. (lynch2024propensitymatchedcomparison pages 8-10): David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S.H. Subramony, George Wilmot, Theresa Zesiewicz, Lisa Weissfeld, and Colin Meyer. Propensity matched comparison of omaveloxolone treatment to friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11:4-16, Sep 2024. URL: https://doi.org/10.1002/acn3.51897, doi:10.1002/acn3.51897. This article has 56 citations and is from a peer-reviewed journal.